A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)

Sakai, H.; Tsurutani, J.; Ozaki, Y.; Ishiguro, H.; Nozawa, K.; Yamanaka, T.; Aogi, K.; Matsumoto, K.; Iwasa, T.; Tokiwa, M.; Tsuneizumi, M.; Miyoshi, Y.; Kitagawa, C.; Yamamoto, M.; Takano, Y.; Imamura, C.K.; Chiba, Y.; Takiguchi, D.; Ezumi, T.; Takano, T.

doi:10.1016/j.annonc.2024.09.001

Annals of Oncology

2025

DOI: 10.1016/j.annonc.2024.09.001

|View full text |Cite

A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)

H. Sakai,

J. Tsurutani,

Y. Ozaki

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2025

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Beyond the usual window: persistent nausea with trastuzumab deruxtecan calls for new management strategies

Jordan

2025

Annals of Oncology

View full text Add to dashboard Cite

Beyond the usual window: persistent nausea with trastuzumab deruxtecan calls for new management strategies

Jordan

2025

Annals of Oncology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)

Cited by 1 publication

References 36 publications

Beyond the usual window: persistent nausea with trastuzumab deruxtecan calls for new management strategies

Beyond the usual window: persistent nausea with trastuzumab deruxtecan calls for new management strategies

Contact Info

Product

Resources

About